10 Stocks Posting Monster Gains Amid Market Downfall

Page 1 of 3

Wall Street fell sharply on Thursday, as investors continued to unload positions amid lingering concerns about the artificial intelligence buildout, while repositioning portfolios ahead of the Federal Reserve’s December meeting.

Against this backdrop, 10 stocks boasted gains, thanks to a flurry of strong earnings. In this article, we identify their names and detail the reasons behind their gains.

To come up with the list, we considered the stocks with more than $1 billion in market capitalization and 5 million shares in trading volume.

The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels

10. Palo Alto Networks Inc. (NASDAW:PANW)

Palo Alto climbed for a second day on Thursday, adding 6.42 percent to close at $361.73 apiece following solid earnings and a higher growth outlook, further supported by plans to expand beyond security services.

In its earnings call on Wednesday, the cybersecurity giant said that it grew its net income by 44 percent to $482 million from $334 million in the same period last year.

Total revenues exceeded company expectations, jumping 39 percent to $3.44 billion from $2.47 billion year-on-year amid the strong demand for security services from customers seeking further protection against cyber threats.

Given the current threat environment, Palo Alto Networks Inc. (NASDAW:PANW) CFO Dipak Golechha said that the company has raised its growth outlook for the fiscal year, with total revenues now expected to grow by 26 to 27 percent, to a range of $14.52 billion to $14.57 billion, versus the 23 to 24 percent projected previously.

NGS-ARR is also now targeted at $11.475 billion to $11.525 billion, representing year-over-year growth of 26 percent to 27 percent, versus 22 to 23 percent earlier.

For the second quarter alone, total revenues are expected at $3.53 billion to $3.55 billion, or an implied growth of 36 to 37 percent.

NGS-ARR is targeted at $10.20 billion to $10.22 billion, or an implied 61 percent year-on-year jump.

Separately, Palo Alto Networks Inc. (NASDAW:PANW) announced plans to acquire Applied Compute in an all-stock transaction valued at $4.5 billion, as it seeks to expand beyond cybersecurity and help businesses securely train, customize, and deploy open-source and open-weight AI models.

9. Full Truck Alliance Co. Ltd. (NYSE:YMM)

Full Truck Alliance rallied for a second day on Thursday, climbing 8.11 percent to close at $9.06 after posting a strong earnings performance in the third quarter of the year, despite the threats of surging oil prices on the shipping industry during the period.

In an updated report, the China-based digital freight platform said that its net income attributable to shareholders jumped by 50 percent to 1.36 billion yuan from 907 million yuan in the same period last year. Total net revenues grew 6.8 percent to 3.586 billion yuan from 3.358 billion yuan year-on-year.

Full Truck Alliance Co. Ltd. (NYSE:YMM) President Langbo Guo underscored the company’s strong transaction revenues during the period, having grown 25 percent year-on-year to 1.82 billion yuan.

Looking ahead, Full Truck Alliance Co. Ltd. is planning to expand its AI adoption through integrating AI agents into capacity dispatching across a wider range of routes to improve fulfillment efficiency.

For the fourth quarter of the year, the company is targeting total net revenues between 3.19 billion yuan to 3.29 billion yuan, representing a flat growth of at least 3.1 percent year-on-year.

In line with the results, its board of directors approved the distribution of cash dividends amounting to $0.0042 per ordinary share, or $0.0840 per American depositary share, to all shareholders as of the January 7, 2027 record. The dividends are payable on January 21.

8. Savara Inc. (NASDAQ:SVRA)

Savara extended its winning streak to a third consecutive day on Thursday, surging 10.38 percent to close at $5.21 apiece, as investors began positioning portfolios ahead of the Food and Drug Administration’s (FDA) decision on its treatment candidate for autoimmune pulmonary alveolar proteinosis (PAP).

The FDA is expected to announce its decision on Savara Inc.’s (NASDAQ:SVRA) biologics license application for Molbreevi on Sunday, November 22.

Earlier this year, the company said that it is focusing on the potential launch of Molbreevi in the US, representing its nearest-term opportunity, supported by a strong balance sheet to ensure commercial readiness. It is also awaiting decisions from regulators in Europe and the UK.

Molbreevi holds the potential to tap more than $2 billion in total addressable market in the US alone, with an estimated 5,500 patients and pricing power of $400,000 to $500,000 per year, as the treatment targets a rare disease with limited therapeutic alternatives.

Molbreevi aside, Savara Inc. holds a strong buy rating from eight analysts covering the stock, the most recent being HC Wainwright and Oppenheimer, reiterating their buy calls with price targets of $10 and $11, respectively. The figures marked upsides of 91.94 percent and 111.13 percent from its latest closing price, signaling a highly optimistic outlook for the stock.

Page 1 of 3